Aligos Therapeutics Inc
ALGS9.670USD
-0.320-3.20%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
67.22MMarket Cap
LossP/E TTM
More Details of Aligos Therapeutics Inc Company
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases. The Company discovers and develops therapeutics for metabolic dysfunction associated steatohepatitis (MASH) and viruses with high unmet medical need, such as chronic hepatitis B (CHB) and coronaviruses. Its advanced drug candidate for MASH is ALG-055009, a small molecule thyroid hormone receptor beta (THR-ß) agonist. It is also progressing oligonucleotide projects for MASH. It is developing a portfolio of differentiated CHB drug candidates, including a small molecule Capsid Assembly Modulator that results in the production of empty viral capsids (CAM-E) and small molecule inhibitors of the Programmed Cell Death Ligand 1 (PD-1/PD-L1) interaction. Its third area of focus is to develop drug candidates with pan-coronavirus antiviral activity. Its pipeline includes ALG-055009, ALG-000184, ALG-125755, and ALG-097558.
Company Info
Ticker SymbolALGS
Company nameAligos Therapeutics Inc
IPO dateOct 16, 2020
CEODr. Lawrence M. Blatt, Ph.D.
Number of employees70
Security typeOrdinary Share
Fiscal year-endOct 16
AddressOne Corporate Dr., 2Nd Floor
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code94080
Phone18004666059
Websitehttps://www.aligos.com/
Ticker SymbolALGS
IPO dateOct 16, 2020
CEODr. Lawrence M. Blatt, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Lawrence M. Blatt, Ph.D.
Dr. Lawrence M. Blatt, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
84.82K
-1.34%
Dr. Julian A. Symons
Dr. Julian A. Symons
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
15.76K
-0.01%
Ms. Lesley Ann Calhoun
Ms. Lesley Ann Calhoun
Chief Financial Officer, Chief Operating Officer, Executive Vice President
Chief Financial Officer, Chief Operating Officer, Executive Vice President
3.61K
--
Dr. K. Peter Hirth, Ph.D.
Dr. K. Peter Hirth, Ph.D.
Independent Director
Independent Director
--
--
Mr. James P. (Jim) Scopa, J.D.
Mr. James P. (Jim) Scopa, J.D.
Independent Director
Independent Director
--
--
Mr. Jordyn Tarazi
Mr. Jordyn Tarazi
Vice President - Investor Relations and Corporate Communications
Vice President - Investor Relations and Corporate Communications
--
--
Ms. Margarita Chavez, J.D.
Ms. Margarita Chavez, J.D.
Independent Director
Independent Director
--
--
Dr. Hardean E. Achneck
Dr. Hardean E. Achneck
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Dr. Bridget A. Martell, M.D.
Dr. Bridget A. Martell, M.D.
Independent Director
Independent Director
--
--
Dr. Heather Preston, M.D.
Dr. Heather Preston, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Lawrence M. Blatt, Ph.D.
Dr. Lawrence M. Blatt, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
84.82K
-1.34%
Dr. Julian A. Symons
Dr. Julian A. Symons
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
15.76K
-0.01%
Ms. Lesley Ann Calhoun
Ms. Lesley Ann Calhoun
Chief Financial Officer, Chief Operating Officer, Executive Vice President
Chief Financial Officer, Chief Operating Officer, Executive Vice President
3.61K
--
Dr. K. Peter Hirth, Ph.D.
Dr. K. Peter Hirth, Ph.D.
Independent Director
Independent Director
--
--
Mr. James P. (Jim) Scopa, J.D.
Mr. James P. (Jim) Scopa, J.D.
Independent Director
Independent Director
--
--
Mr. Jordyn Tarazi
Mr. Jordyn Tarazi
Vice President - Investor Relations and Corporate Communications
Vice President - Investor Relations and Corporate Communications
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Tue, Aug 19
Updated: Tue, Aug 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Woodline Partners LP
9.69%
Deep Track Capital LP
8.30%
Roche Holding AG
8.24%
Alyeska Investment Group, L.P.
7.70%
Sio Capital Management, LLC
6.28%
Other
59.80%
Shareholders
Shareholders
Proportion
Woodline Partners LP
9.69%
Deep Track Capital LP
8.30%
Roche Holding AG
8.24%
Alyeska Investment Group, L.P.
7.70%
Sio Capital Management, LLC
6.28%
Other
59.80%
Shareholder Types
Shareholders
Proportion
Hedge Fund
40.62%
Holding Company
8.24%
Investment Advisor/Hedge Fund
5.04%
Investment Advisor
4.14%
Individual Investor
2.13%
Research Firm
0.57%
Venture Capital
0.26%
Other
39.01%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
98
3.94M
73.72%
+1.04M
2025Q1
107
3.92M
73.74%
+933.68K
2024Q4
102
2.24M
64.56%
-201.23K
2024Q3
108
2.31M
72.88%
-178.35K
2024Q2
119
2.51M
80.85%
+118.52K
2024Q1
173
2.47M
81.48%
-70.94K
2023Q4
186
2.43M
84.05%
+688.78K
2023Q3
190
1.29M
80.24%
-480.15K
2023Q2
195
1.32M
81.61%
-477.61K
2023Q1
201
1.36M
85.00%
-395.08K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Woodline Partners LP
315.38K
5.93%
+315.38K
--
Mar 31, 2025
Deep Track Capital LP
444.11K
8.36%
+200.00K
+81.93%
Mar 31, 2025
Roche Holding AG
441.04K
8.3%
-1.00
-0.00%
Mar 06, 2025
Alyeska Investment Group, L.P.
412.00K
7.75%
+412.00K
--
Mar 31, 2025
Sio Capital Management, LLC
180.72K
3.4%
+180.72K
--
Mar 31, 2025
Tang Capital Management, LLC
141.13K
2.66%
+141.13K
--
Mar 31, 2025
Adage Capital Management, L.P.
465.00K
8.75%
+140.00K
+43.08%
Mar 31, 2025
The Vanguard Group, Inc.
140.75K
2.65%
+43.99K
+45.46%
Mar 31, 2025
Readystate Asset Management LP
45.40K
0.85%
+45.40K
--
Mar 31, 2025
Blatt (Lawrence M)
84.82K
1.6%
-1.15K
-1.34%
Mar 10, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 15, 2024
Merger
25→1
Aug 15, 2024
Merger
25→1
Aug 15, 2024
Merger
25→1
Aug 15, 2024
Merger
25→1
Date
Type
Ratio
Aug 15, 2024
Merger
25→1
Aug 15, 2024
Merger
25→1
Aug 15, 2024
Merger
25→1
Aug 15, 2024
Merger
25→1
